Davis Todd C

Average Profitability
24.73%
Insider Buys Quantity
3
Insider Buys Sum
$644,509.30
Insider Sells Quantity
8
Insider Sells Sum
$6.2M

Insider Activity of Davis Todd C

According to the SEC Form 4 filings, Davis Todd C, being in a position of

  1. Chief Executive Officer at Ligand Pharmaceuticals Incorporated,
    оver the last 12 months, has bought 2500 shares for $243,481, and sold 0 shares,
    over all time since 2011-08-10, has bought 21500 shares for $644,509, and sold 36170 shares for $6.01M.

The largest purchase of all time was on 2024-08-08 and amounted to 2500 shares of Ligand Pharmaceuticals Incorporated for $243,481.

The largest sale of all time was on 2018-02-27 and amounted to 12335 shares of Ligand Pharmaceuticals Incorporated for $1.87M.

Biography of Davis Todd C

No biography is available at this moment.

2024-08-08PurchaseLigand Pharmaceuticals Incorporated
LGND
Chief Executive Officer
2,500
0.014%
$97.39$243,481+6.94%
2023-09-22PurchaseLigand Pharmaceuticals Incorporated
LGND
CHIEF EXECUTIVE OFFICER
4,000
0.0232%
$59.38$237,529+24.41%
2020-04-28SaleVaxart, Inc.
VXRT
director
60,000
0.0805%
$3.27$196,500+105.5%
2018-10-08SaleLigand Pharmaceuticals Incorporated
LGND
director
2,500
0.0122%
$253.99$634,978-52.26%
2018-08-17SaleLigand Pharmaceuticals Incorporated
LGND
director
3,167
0.0145%
$239.50$758,497-49.81%
2018-08-16SaleLigand Pharmaceuticals Incorporated
LGND
director
5,833
0.0276%
$239.93$1.4M-48%
2018-02-27SaleLigand Pharmaceuticals Incorporated
LGND
director
12,335
0.0584%
$151.90$1.87M+13.07%
2018-02-26SaleLigand Pharmaceuticals Incorporated
LGND
director
4,835
0.0229%
$153.58$742,536+12.17%
2014-03-19SaleLigand Pharmaceuticals Incorporated
LGND
director
5,000
0.0249%
$79.63$398,147-28.77%
2014-03-18SaleLigand Pharmaceuticals Incorporated
LGND
director
2,500
0.0121%
$79.45$198,637-30.48%
2011-08-10PurchaseLigand Pharmaceuticals Incorporated
LGND
director
15,000
0.0745%
$10.90$163,500+24.73%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.